Beam Therapeutics ($BEAM) announced it will present updated Phase 1/2 clinical trial data for BEAM-302, its investigational base-editing therapy for Alpha-1 Antitrypsin Deficiency (AATD), during a late-breaking oral presentation at the European Respiratory Society (ERS) Congress 2026. The company will also host an investor webcast on September 8, 2026, at 7:00 a.m. ET to discuss the updated clinical results. 🔑 Key Highlights 🧬 Updated Phase 1/2 data for BEAM-302 to be presented 🫁 Targets Alpha-1 Antitrypsin Deficiency (AATD) 🎤 Selected for a late-breaking oral presentation at the ERS Congress 2026 📅 Investor webcast: September 8, 2026, at 7:00 a.m. ET 📈 Highlights continued clinical progress for Beam's base-editing pipeline